| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $6.6M | +900.9% |
| SG&A Expense | $14.8M | — |
| Operating Income | -$21.4M | — |
| Net Income | -$61.0M | — |
| EPS (Basic) | -$2.41 | — |
| EPS (Diluted) | -$0.57 | -5600.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $23.7M | +252.5% |
| Current Assets | $24.4M | — |
| Total Assets | $24.7M | — |
| Current Liabilities | $2.4M | +1424.2% |
| Total Liabilities | $2.4M | +1424.2% |
| Stockholders' Equity | $22.3M | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$13.1M | — |
| Capital Expenditures | $43K | +1534.8% |
| Investing Cash Flow | -$43K | -1534.8% |
| Financing Cash Flow | $30.1M | — |
| Free Cash Flow | -$13.1M | — |